Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atea Pharmaceuticals Inc AVIR

Healthcare
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is... see more

Recent & Breaking News (NDAQ:AVIR)

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

GlobeNewswire March 27, 2024

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire February 28, 2024

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

GlobeNewswire February 21, 2024

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Atea Pharmaceuticals, Inc. (AVIR) and Encourages Investors to Contact the Firm

Accesswire February 13, 2024

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

GlobeNewswire January 8, 2024

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

GlobeNewswire November 13, 2023

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 8, 2023

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

GlobeNewswire November 8, 2023

Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

GlobeNewswire November 2, 2023

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

GlobeNewswire November 1, 2023

Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

GlobeNewswire September 6, 2023

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 8, 2023

Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

GlobeNewswire August 1, 2023

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

GlobeNewswire June 15, 2023

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

GlobeNewswire June 5, 2023

Atea Pharmaceuticals' Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

GlobeNewswire May 30, 2023

Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

GlobeNewswire May 23, 2023

Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 8, 2023

Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023

GlobeNewswire May 1, 2023